S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:GTHX

G1 Therapeutics Competitors

$22.10
-0.26 (-1.16 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.94
Now: $22.10
$22.87
50-Day Range
$17.59
MA: $24.41
$32.59
52-Week Range
$8.80
Now: $22.10
$37.07
Volume1.90 million shs
Average Volume1.76 million shs
Market Capitalization$840.82 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44

Competitors

G1 Therapeutics (NASDAQ:GTHX) Vs. KRTX, AGIO, MOR, FOLD, PCRX, and RCKT

Should you be buying GTHX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to G1 Therapeutics, including Karuna Therapeutics (KRTX), Agios Pharmaceuticals (AGIO), MorphoSys (MOR), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX), and Rocket Pharmaceuticals (RCKT).

G1 Therapeutics (NASDAQ:GTHX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Karuna TherapeuticsN/A-13.91%-13.72%

Analyst Recommendations

This is a breakdown of current recommendations for G1 Therapeutics and Karuna Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Karuna Therapeutics001103.00

G1 Therapeutics currently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Karuna Therapeutics has a consensus target price of $140.40, indicating a potential upside of 12.36%. Given G1 Therapeutics' higher possible upside, analysts plainly believe G1 Therapeutics is more favorable than Karuna Therapeutics.

Earnings & Valuation

This table compares G1 Therapeutics and Karuna Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-33.96

Karuna Therapeutics is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

G1 Therapeutics (NASDAQ:GTHX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Analyst Recommendations

This is a breakdown of current recommendations for G1 Therapeutics and Agios Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Agios Pharmaceuticals02902.82

G1 Therapeutics currently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Agios Pharmaceuticals has a consensus target price of $67.1818, indicating a potential upside of 41.61%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe G1 Therapeutics is more favorable than Agios Pharmaceuticals.

Earnings & Valuation

This table compares G1 Therapeutics and Agios Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
Agios Pharmaceuticals$117.91 million27.91$-411,470,000.00($6.86)-6.92

G1 Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Summary

G1 Therapeutics beats Agios Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
MorphoSys8.76%4.51%2.25%

Analyst Recommendations

This is a breakdown of current recommendations for G1 Therapeutics and MorphoSys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
MorphoSys05302.38

G1 Therapeutics currently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe G1 Therapeutics is more favorable than MorphoSys.

Earnings & Valuation

This table compares G1 Therapeutics and MorphoSys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
MorphoSys$80.43 million40.65$-115,380,000.00($0.91)-27.31

MorphoSys has higher revenue and earnings than G1 Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Summary

MorphoSys beats G1 Therapeutics on 7 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Amicus Therapeutics-120.18%-73.81%-36.10%

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for G1 Therapeutics and Amicus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Amicus Therapeutics07502.42

G1 Therapeutics currently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Amicus Therapeutics has a consensus target price of $20.7917, indicating a potential upside of 69.31%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe G1 Therapeutics is more favorable than Amicus Therapeutics.

Earnings & Valuation

This table compares G1 Therapeutics and Amicus Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
Amicus Therapeutics$182.24 million17.56$-356,390,000.00($1.31)-9.37

G1 Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

G1 Therapeutics beats Amicus Therapeutics on 10 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 5.8% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and Pacira BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Pacira BioSciences29.95%10.71%4.88%

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for G1 Therapeutics and Pacira BioSciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Pacira BioSciences04702.64

G1 Therapeutics presently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Pacira BioSciences has a consensus target price of $74.6364, indicating a potential upside of 1.55%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe G1 Therapeutics is more favorable than Pacira BioSciences.

Valuation & Earnings

This table compares G1 Therapeutics and Pacira BioSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
Pacira BioSciences$421.03 million7.58$-11,020,000.00$0.8685.47

Pacira BioSciences has higher revenue and earnings than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pacira BioSciences beats G1 Therapeutics on 7 of the 12 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 41.4% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares G1 Therapeutics and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Rocket PharmaceuticalsN/A-35.81%-27.52%

Risk and Volatility

G1 Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for G1 Therapeutics and Rocket Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Rocket Pharmaceuticals011202.92

G1 Therapeutics presently has a consensus target price of $49.1667, indicating a potential upside of 122.47%. Rocket Pharmaceuticals has a consensus target price of $57.8889, indicating a potential upside of 4.15%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe G1 Therapeutics is more favorable than Rocket Pharmaceuticals.

Valuation & Earnings

This table compares G1 Therapeutics and Rocket Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-6.76
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-35.18

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than G1 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats G1 Therapeutics on 6 of the 11 factors compared between the two stocks.


G1 Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
KRTX
Karuna Therapeutics
1.6$124.96-3.3%$3.35 billionN/A-62.17Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$47.44-6.0%$3.29 billion$117.91 million-9.62Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
MorphoSys logo
MOR
MorphoSys
0.4$24.85-2.9%$3.27 billion$80.43 million118.34News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.28-2.9%$3.20 billion$182.24 million-10.68Upcoming Earnings
Gap Up
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$73.50-1.3%$3.19 billion$421.03 million25.88Earnings Announcement
Analyst Report
News Coverage
Gap Down
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$55.58-6.7%$3.07 billionN/A-30.54Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$19.04-2.1%$3.03 billion$1.17 billion-41.39
OPKO Health logo
OPK
OPKO Health
1.9$4.50-1.8%$3.02 billion$901.90 million-25.00Gap Down
ALXO
ALX Oncology
2.1$80.29-3.0%$2.98 billionN/A0.00Upcoming Earnings
News Coverage
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$25.15-1.6%$2.95 billion$306.49 million28.26Earnings Announcement
Gap Down
VIE
Viela Bio
0.8$53.20-0.5%$2.92 billion$50 million-7.58Upcoming Earnings
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.43-0.7%$2.84 billion$60,000.00-11.00Earnings Announcement
Insider Selling
News Coverage
Gap Up
Xencor logo
XNCR
Xencor
1.0$49.27-5.1%$2.83 billion$156.70 million-35.19Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$71.50-0.5%$2.74 billion$644.77 million-10.20
PRLD
Prelude Therapeutics
1.0$62.33-3.2%$2.72 billionN/A0.00Upcoming Earnings
News Coverage
IGMS
IGM Biosciences
1.5$87.43-4.0%$2.68 billionN/A-37.20Analyst Upgrade
News Coverage
Gap Down
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$42.60-2.1%$2.63 billion$2.11 million-9.22Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$6.74-3.1%$2.62 billion$429.76 million-134.77Earnings Announcement
News Coverage
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.78-2.7%$2.52 billion$25 million-8.76
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$67.36-1.5%$2.52 billionN/A-25.04Upcoming Earnings
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.22-1.3%$2.38 billion$120.28 million-149.72
Cryoport logo
CYRX
Cryoport
1.3$59.44-0.3%$2.36 billion$33.94 million-102.48Upcoming Earnings
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$35.26-2.9%$2.29 billion$15 million-18.46Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$41.71-0.1%$2.08 billion$963.01 million12.95
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$22.46-3.2%$2.04 billionN/A-7.99Gap Up
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.98-4.9%$2.02 billion$23.90 million-16.76Earnings Announcement
High Trading Volume
News Coverage
Gap Down
HRMY
Harmony Biosciences
1.3$35.47-2.0%$2.02 billionN/A0.00Upcoming Earnings
STOK
Stoke Therapeutics
1.0$59.89-2.3%$2.00 billionN/A-33.27Insider Selling
GBIO
Generation Bio
1.3$34.92-1.3%$1.95 billionN/A0.00Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.19-1.5%$1.87 billionN/A-10.95Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
NGM
NGM Biopharmaceuticals
1.7$26.72-3.9%$1.84 billion$103.54 million-20.09Gap Up
ADCT
ADC Therapeutics
1.6$26.59-7.1%$1.83 billion$2.34 million-11.27Upcoming Earnings
Endo International logo
ENDP
Endo International
1.4$7.93-17.4%$1.83 billion$2.91 billion-11.66Earnings Announcement
News Coverage
Gap Up
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.00-4.1%$1.78 billion$320,000.00-9.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
PAND
Pandion Therapeutics
1.1$60.20-0.6%$1.78 billion$970,000.000.00Upcoming Earnings
Analyst Report
High Trading Volume
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$26.26-3.5%$1.75 billion$410,000.00-5.71Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.04-1.3%$1.74 billion$34.51 million-16.27Upcoming Earnings
Analyst Downgrade
News Coverage
STTK
Shattuck Labs
1.1$41.30-1.8%$1.72 billionN/A0.00Gap Up
ARQT
Arcutis Biotherapeutics
1.6$34.17-0.2%$1.71 billionN/A-3.70
ZNTL
Zentalis Pharmaceuticals
1.6$42.04-3.9%$1.71 billionN/A0.00Upcoming Earnings
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$48.87-16.9%$1.70 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.75-0.3%$1.70 billion$82.27 million-21.34
PMVP
PMV Pharmaceuticals
1.2$37.63-3.8%$1.68 billionN/A0.00Gap Up
PRAX
Praxis Precision Medicines
1.8$43.50-4.3%$1.66 billionN/A0.00Gap Down
Zymeworks logo
ZYME
Zymeworks
1.8$36.31-3.2%$1.66 billion$29.54 million-9.63Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
FREQ
Frequency Therapeutics
1.5$49.21-0.7%$1.66 billion$28.95 million-70.30Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.08-0.2%$1.64 billion$145.97 million-7.32Earnings Announcement
Analyst Revision
News Coverage
ORGO
Organogenesis
1.0$15.21-4.6%$1.64 billion$260.98 million-253.50Gap Up
uniQure logo
QURE
uniQure
1.9$36.70-0.8%$1.63 billion$7.28 million-9.73Upcoming Earnings
Unusual Options Activity
KRON
Kronos Bio
1.8$29.07-0.3%$1.63 billionN/A0.00Upcoming Earnings
News Coverage
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.